AI assistant
NYRADA INC. — Board/Management Information 2020
Dec 13, 2020
65469_rns_2020-12-13_1ecb0197-97d2-4dfb-8486-31a03ab5283f.pdf
Board/Management Information
Open in viewerOpens in your device viewer
14 December 2020
Sydney, Australia
==> picture [596 x 114] intentionally omitted <==
Appointment of New Auditor
Sydney, 14 December 2020 : Nyrada Inc (ASX: NYR), in accordance with Listing Rule 3.16.3, announces that William Buck Audit (Vic) Pty Ltd has been appointed as auditor of the Company. The appointment follows the resignation of Nexia Sydney Audit Pty Ltd.
The change of auditor arose as a result of a tender process undertaken by the Company following the completion of the annual audit for the period ending 30 June 2020.
The Company wishes to thank Nexia and Mr Stephen Fisher (Director) for their services to the company over recent years.
About Nyrada Inc
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory/autoimmune diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.
-ENDS-
Authorised by Mr John Moore, Non-Executive Chairman, on behalf of the Board.
Investor & Corporate Enquiries:
Prue Kelly T: 0459 022 445
David Franks
T: 02 8072 1400 E: [email protected]
Media Enquiries:
Catherine Strong Citadel-MAGNUS
T: 02 8234 0111
Nyrada Inc. Suite 3, Level 4, 828 Pacific Highway GORDON, NSW 2072
Nyrada Inc. ARBN 625 401 818